Journal of Clinical Endocrinology & Metabolism, Vol 81, 3450-3454, Copyright © 1996 by Endocrine Society

ARTICLES

Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption--a clinical research center study

A Grey, MA Mitnick, S Shapses, A Ellison, C Gundberg and K Insogna
Department of Endocrinology, Yale University School of Medicine, New Haven, Connecticut 06520, USA.

The pathogenesis of PTH-induced bone loss is uncertain. Experimental evidence suggests that PTH induces the production by osteoblasts of the bone-resorbing cytokine, interleukin-6. We measured the circulating levels of interleukin-6, tumor necrosis factor-alpha, and interleukin-1 beta and examined their relationship to biochemical markers of bone turnover in 38 patients with primary hyperparathyroidism (7 of whom also were studied after successful parathyroid adenomectomy), 6 patients with hypoparathyroidism, and 12 subjects with normal parathyroid function. The patients with untreated primary hyperparathyroidism had mean serum levels of interleukin-6 that were 16- fold higher than control values (mean +/- SEM; primary hyperparathyroidism 18.6 +/- 2.1 pg/mL, controls 1.1 +/- 0.1; P < 0.001). Circulating levels of interleukin-6 soluble receptor (primary hyperparathyroidism 41.7 +/- 1.2 ng/ mL, controls 25.1 +/- 1.0; P < 0.001), and tumor necrosis factor-alpha (primary hyperparathyroidism 11.6 +/- 0.8 pg/mL, controls 2.5 +/- 0.2; P < 0.001) were also elevated. After successful parathyroid adenomectomy, levels of each of these cytokines fell into the normal range. The mean levels of interleukin-6, its soluble receptor, and tumor necrosis factor-alpha in the subjects with hypoparathyroidism were lower than control values (P < 0.001 for each variable). There was no difference between subjects with primary hyperparathyroidism and controls in the circulating level of interleukin-1 beta. In the subjects with untreated primary hyperparathyroidism, serum levels of interleukin-6 correlated strongly with those of intact PTH (r = 0.47, P = 0.003) and biochemical markers of bone resorption: serum deoxypyridinoline (r = 0.93, P < 0.001), serum type I collagen carboxyterminal telopeptide (r = 0.87, P < 0.001), urinary pyridinoline (r = 0.81, P < 0.001), and urinary deoxypyridinoline (r = 0.63, P = 0.005). Levels of tumor necrosis factor-alpha correlated less strongly with the same variables: PTH (r = 0.41, P = 0.01), serum deoxypyridinoline (r = 0.48, P = 0.002), serum type I collagen carboxyterminal telopeptide (r = 0.46, P = 0.004), urinary pyridinoline (r = 0.61, P = 0.008), and urinary deoxypyridinoline (r = 0.61, P = 0.007). Levels of interleukin-6 also correlated with those of tumor necrosis factor-alpha (r = 0.44, P = 0.005). Multiple regression analysis indicated that interleukin-6, but not tumor necrosis factor-alpha, was independently predictive of bone resorption. We conclude that serum levels of interleukin-6 and tumor necrosis factor-alpha are increased in patients with primary hyperparathyroidism and are normalized by successful surgical treatment. The finding that these cytokines correlate with biochemical markers of bone resorption suggests that they play a role in the pathogenesis of bone loss in primary hyperparathyroidism.

This article has been cited by other articles:

				L. Duplomb, M. Baud'huin, C. Charrier, M. Berreur, V. Trichet, F. Blanchard, and D. Heymann Interleukin-6 Inhibits Receptor Activator of Nuclear Factor {kappa}B Ligand-Induced Osteoclastogenesis by Diverting Cells into the Macrophage Lineage: Key Role of Serine727 Phosphorylation of Signal Transducer and Activator of Transcription 3 Endocrinology, July 1, 2008; 149(7): 3688 - 3697. [Abstract] [Full Text] [PDF]

				I. A. Nakchbandi, R. Lang, B. Kinder, and K. L. Insogna The Role of the Receptor Activator of Nuclear Factor-{kappa}B Ligand/Osteoprotegerin Cytokine System in Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 967 - 973. [Abstract] [Full Text] [PDF]

				I. Sermet-Gaudelus, J. C. Souberbielle, J. C. Ruiz, S. Vrielynck, B. Heuillon, I. Azhar, A. Cazenave, E. Lawson-Body, F. Chedevergne, and G. Lenoir Low Bone Mineral Density in Young Children with Cystic Fibrosis Am. J. Respir. Crit. Care Med., May 1, 2007; 175(9): 951 - 957. [Abstract] [Full Text] [PDF]

				S. Reppe, L. Stilgren, B. Abrahamsen, O. K. Olstad, F. Cero, K. Brixen, L. S. Nissen-Meyer, and K. M. Gautvik Abnormal muscle and hematopoietic gene expression may be important for clinical morbidity in primary hyperparathyroidism Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1465 - E1473. [Abstract] [Full Text] [PDF]

				Y. Sun, R. A. Ahokas, S. K. Bhattacharya, I. C. Gerling, L. D. Carbone, and K. T. Weber Oxidative stress in aldosteronism Cardiovasc Res, July 15, 2006; 71(2): 300 - 309. [Abstract] [Full Text] [PDF]

				S Corbetta, L Vicentini, S Ferrero, A Lania, G Mantovani, D Cordella, P Beck-Peccoz, and A Spada Activity and function of the nuclear factor kappaB pathway in human parathyroid tumors Endocr. Relat. Cancer, December 1, 2005; 12(4): 929 - 937. [Abstract] [Full Text] [PDF]

				A Iida-Klein, S S. Lu, R Kapadia, M Burkhart, A Moreno, D W Dempster, and R Lindsay Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice J. Endocrinol., September 1, 2005; 186(3): 549 - 557. [Abstract] [Full Text] [PDF]

				J. E. Morley and R. N. Baumgartner Cytokine-Related Aging Process J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2004; 59(9): M924 - M929. [Full Text] [PDF]

				E. C. Buxton, W. Yao, and N. E. Lane Changes in Serum Receptor Activator of Nuclear Factor-{kappa}B Ligand, Osteoprotegerin, and Interleukin-6 Levels in Patients with Glucocorticoid-Induced Osteoporosis Treated with Human Parathyroid Hormone (1-34) J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3332 - 3336. [Abstract] [Full Text] [PDF]

				C S Haworth, P L Selby, A K Webb, L Martin, J S Elborn, L D Sharples, and J E Adams Inflammatory related changes in bone mineral content in adults with cystic fibrosis Thorax, July 1, 2004; 59(7): 613 - 617. [Abstract] [Full Text] [PDF]

				G. Passeri, G. Pini, L. Troiano, R. Vescovini, P. Sansoni, M. Passeri, P. Gueresi, R. Delsignore, M. Pedrazzoni, and C. Franceschi Low Vitamin D Status, High Bone Turnover, and Bone Fractures in Centenarians J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5109 - 5115. [Abstract] [Full Text] [PDF]

				I. A. Nakchbandi, M. A. Mitnick, R. Lang, C. Gundberg, B. Kinder, and K. Insogna Circulating Levels of Interleukin-6 Soluble Receptor Predict Rates of Bone Loss in Patients with Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4946 - 4951. [Abstract] [Full Text] [PDF]

				P. Palmqvist, E. Persson, H. H. Conaway, and U. H. Lerner IL-6, Leukemia Inhibitory Factor, and Oncostatin M Stimulate Bone Resorption and Regulate the Expression of Receptor Activator of NF-{kappa}B Ligand, Osteoprotegerin, and Receptor Activator of NF-{kappa}B in Mouse Calvariae J. Immunol., September 15, 2002; 169(6): 3353 - 3362. [Abstract] [Full Text] [PDF]

				M. Pazianas, M. Zaidi, S. Schmaldienst, E. Dittrich, B. Watschinger, and P. Pietschmann Two underlying diseases causing hypercalcaemia? Nephrol. Dial. Transplant., June 1, 2002; 17(6): 1141 - 1141. [Full Text] [PDF]

				U. S. Masiukiewicz, M. Mitnick, B. I. Gulanski, and K. L. Insogna Evidence that the IL-6/IL-6 Soluble Receptor Cytokine System Plays a Role in the Increased Skeletal Sensitivity to PTH in Estrogen-Deficient Women J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2892 - 2898. [Abstract] [Full Text] [PDF]

				J J McInerney, A Breakell, W Madira, T G Davies, and P A Evans Accidental hypothermia and active rewarming: the metabolic and inflammatory changes observed above and below 32{degrees}C Emerg. Med. J., May 1, 2002; 19(3): 219 - 223. [Abstract] [Full Text] [PDF]

				I. A. Nakchbandi, M. A. Mitnick, U. S. Masiukiewicz, B. h. Sun, and K. L. Insogna IL-6 Negatively Regulates IL-11 Production in Vitro and in Vivo Endocrinology, September 1, 2001; 142(9): 3850 - 3856. [Abstract] [Full Text] [PDF]

				M. A. Mitnick, A. Grey, U. Masiukiewicz, M. Bartkiewicz, L. Rios-Velez, S. Friedman, L. Xu, M. C. Horowitz, and K. Insogna Parathyroid hormone induces hepatic production of bioactive interleukin-6 and its soluble receptor Am J Physiol Endocrinol Metab, March 1, 2001; 280(3): E405 - E412. [Abstract] [Full Text] [PDF]

				A. A. IONESCU, L. S. NIXON, W. D. EVANS, M. D. STONE, V. LEWIS-JENKINS, K. CHATHAM, and D. J. SHALE Bone Density, Body Composition, and Inflammatory Status in Cystic Fibrosis Am. J. Respir. Crit. Care Med., September 1, 2000; 162(3): 789 - 794. [Abstract] [Full Text]

				A. Khan and J. Bilezikian Primary hyperparathyroidism: pathophysiology and impact on bone Can. Med. Assoc. J., July 1, 2000; 163(2): 184 - 187. [Abstract] [Full Text] [PDF]

				U. S. Masiukiewicz, M. Mitnick, A. B. Grey, and K. L. Insogna Estrogen Modulates Parathyroid Hormone-Induced Interleukin-6 Production in Vivo and in Vitro Endocrinology, July 1, 2000; 141(7): 2526 - 2531. [Abstract] [Full Text] [PDF]

				A. Grey, M.-A. Mitnick, U. Masiukiewicz, B.-H. Sun, S. Rudikoff, R. L. Jilka, S. C. Manolagas, and K. Insogna A Role for Interleukin-6 in Parathyroid Hormone-Induced Bone Resorption in Vivo Endocrinology, October 1, 1999; 140(10): 4683 - 4690. [Abstract] [Full Text]

				P. V. N. Bodine, H. A. Harris, and B. S. Komm Suppression of Ligand-Dependent Estrogen Receptor Activity by Bone-Resorbing Cytokines in Human Osteoblasts Endocrinology, June 1, 1999; 140(6): 2439 - 2451. [Abstract] [Full Text]